Last updated: 2026-09-16 12:18:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Agenus Inc. (AGEN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $7.16, with a market capitalisation of $321.00M and a P/E ratio of 3.51. Over the past 52 weeks, its price has ranged from $2.71 to $8.85. This page covers its latest market performance, valuation, price trends and company information.
$321.00M | |
$7.13 | |
$1,884.00 | |
$1.38 | |
$7.16 | |
15.00 | |
4.24M | |
3.51 | |
$8.85 | |
$2.71 | |
-- | |
-- |
Agenus Inc. (AGEN) is trading at $7.16 in pre-market trading as of 2026-09-16 11:02:00, down 0.01% ($0.00) from the previous close of $7.16
Pre-market trading shows how investors are pricing AGEN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Agenus Inc. (AGEN) moved from $8.24 to $7.16, representing a decline of 13.12% ($1.08).
The stock traded between $6.66 and $8.38 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 979.46 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 72.5%
AGEN is currently trading at $7.16, placing it 72.5% of the way from its 52-week low of $2.71 to its 52-week high of $8.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 81 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Agenus Inc. (AGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.